期刊
CELLS
卷 10, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/cells10020265
关键词
glioblastoma; immunotherapy; tumor model; stem cell; organoid; heterogeneity; immunosuppression; microenvironment
类别
资金
- Slovenian Research Agency [P1-0245, Z3-1870, BI-US/19-21-021]
- European Program of Cross-Border Cooperation for Slovenia-Italy Interreg TRANS-GLIOMA
Glioblastoma, the most common brain malignant tumor in adults, poses challenges for effective immunotherapy due to its intracranial location, tumor heterogeneity, and immunosuppressive microenvironment. Various promising immunotherapeutic strategies, such as vaccines, oncolytic viruses, immune checkpoint inhibitors, and adoptive cell transfer, have been applied in an attempt to promote tumor eradication and overcome immune resistance. However, discrepancies exist between preclinical studies and clinical studies in evaluating the efficiency of these strategies on glioblastoma patients.
Glioblastoma is the most common brain malignant tumor in the adult population, and immunotherapy is playing an increasingly central role in the treatment of many cancers. Nevertheless, the search for effective immunotherapeutic approaches for glioblastoma patients continues. The goal of immunotherapy is to promote tumor eradication, boost the patient's innate and adaptive immune responses, and overcome tumor immune resistance. A range of new, promising immunotherapeutic strategies has been applied for glioblastoma, including vaccines, oncolytic viruses, immune checkpoint inhibitors, and adoptive cell transfer. However, the main challenges of immunotherapy for glioblastoma are the intracranial location and heterogeneity of the tumor as well as the unique, immunosuppressive tumor microenvironment. Owing to the lack of appropriate tumor models, there are discrepancies in the efficiency of various immunotherapeutic strategies between preclinical studies (with in vitro and animal models) on the one hand and clinical studies (on humans) on the other hand. In this review, we summarize the glioblastoma characteristics that drive tolerance to immunotherapy, the currently used immunotherapeutic approaches against glioblastoma, and the most suitable tumor models to mimic conditions in glioblastoma patients. These models are improving and can more precisely predict patients' responses to immunotherapeutic treatments, either alone or in combination with standard treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据